Clinical Trial Update: Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation

View source ↗

Summary

This update describes a study evaluating circulating progastrin (hPG80) as a diagnostic biomarker for neuroendocrine tumors in patients with an MEN1 mutation, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Endocrine Neoplasia Type
• Neuroendocrine Tumors

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Neuroendocrine Tumors, MEN1 Mutation | Status: RECRUITING